Helsinn Healthcare S. A. v. Teva Pharmaceuticals USA, Inc.
The Supreme Court ruled that selling an invention to a partner company under a confidentiality agreement can still count as putting the invention "on sale," even though the public never learned the invention's details.
The decision means a 2011 patent-law overhaul did not change decades-old rules about secret commercial sales, so drugmakers and other inventors can still lose patent rights if they sell a product commercially before filing, even behind closed doors.
How it got here: A federal trial court ruled the sale didn't invalidate the patent; the Federal Circuit reversed; Helsinn asked the Supreme Court to review that ruling.
The Case in Depth
What happened
Helsinn, a drug company, developed a chemotherapy nausea drug using palonosetron and struck licensing and supply deals with MGI Pharma to sell a 0.25 mg dose, requiring MGI to keep details confidential. Helsinn later patented that dose. When Teva sought to sell a generic version, Helsinn sued for infringement, and Teva argued the patent was invalid because the dose had already been sold commercially more than a year before Helsinn's patent filing.
The question before the Court
If a company sells its invention to a business partner who must keep it secret, does that sale still count as putting the invention "on sale" and bar a later patent?
Why it matters
Companies, especially in pharmaceuticals and technology, often line up distribution or supply deals before an invention is publicly known. This ruling confirms that such confidential commercial deals still start the clock on the one-year deadline to file for patent protection, so businesses must time their patent filings carefully around private sales, not just public disclosures.
What changes now
This is a final merits decision resolving the legal question, and it affirms the Federal Circuit's ruling that Helsinn's patent is invalid because the invention was sold before the filing deadline. Inventors and companies negotiating confidential sales or licensing deals must now plan patent filings around those private transactions, not just around public announcements.
How the Court got there
The legal reasoning, step by step
- The Court looked to its own pre-2011 precedent interpreting the older version of the patent law's "on sale" bar, which asked only whether the invention was the subject of a commercial offer for sale and ready for patenting — not whether the public knew the invention's details.
- Federal appeals courts had built on that precedent by explicitly ruling that even 'secret sales' kept confidential from the public could still invalidate a later patent.
- Applying the legal presumption that when Congress reuses the exact same words from an old statute in a new one, it means to keep the same meaning courts had already given those words, the Court found Congress carried forward the settled meaning of 'on sale' when it passed the 2011 patent law overhaul (the America Invents Act).
- The Court rejected the argument that a newly added phrase, 'or otherwise available to the public,' silently narrowed 'on sale' to only public sales, reasoning that such catchall phrases are meant to sweep in extra situations, not quietly rewrite well-established terms.
- Because the confidential sale here matched the kind of transaction that already counted as 'on sale' under the older law, the Court concluded the same result applies under the new law.
Doctrinal impact
Cases affected by this decision
Reaffirms Pfaff v. Wells Electronics, Inc. (525 U. S. 55)
The Court relied on this case's two-part test for when an invention is 'on sale' under the older patent law.